Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar
Zomedica (OTCQB:ZOMDF) announced a Fourth Friday at Four webinar on October 24, 2025 at 4:00 p.m. ET to showcase the VETGuardian Zero Touch monitoring platform.
The session will review how the VETGuardian monitor uses radar and imaging technology to capture continuous vital signs—heart rate, respiration, and body temperature—without wires or contact. The release cites a $720 million veterinary monitoring market in 2025, projected to grow at ~8% annually through 2029, and positions VETGuardian as a workflow- and welfare-improving tool that complements Zomedica's diagnostics and therapeutics.
The webinar is offered via live webcast and registration details are available on the company website.
Zomedica (OTCQB:ZOMDF) ha annunciato un webinar Fourth Friday at Four il 24 ottobre 2025 alle 16:00 ET per presentare la piattaforma di monitoraggio VETGuardian Zero Touch.
La sessione illustrerà come il monitor VETGuardian utilizza tecnologia radar e imaging per rilevare segnali vitali continui—frequenza cardiaca, respirazione e temperatura corporea—senza cavi o contatto. Il comunicato cita un mercato di monitoraggio veterinario da $720 milioni nel 2025, previsto crescere di ~8% annuo fino al 2029, e presenta VETGuardian come uno strumento che migliora il flusso di lavoro e il benessere, complementare alle diagnostiche e terapie di Zomedica.
Il webinar è offerto tramite webcast in diretta e i dettagli di registrazione sono disponibili sul sito dell'azienda.
Zomedica (OTCQB:ZOMDF) anunció un seminario web Fourth Friday at Four el 24 de octubre de 2025 a las 4:00 p. m. ET para presentar la plataforma de monitoreo VETGuardian Zero Touch.
La sesión revisará cómo el monitor VETGuardian utiliza tecnología de radar e imágenes para capturar signos vitales continuos—frecuencia cardíaca, respiración y temperatura corporal—sin cables ni contacto. El comunicado cita un mercado de monitoreo veterinario de $720 millones en 2025, proyectado a crecer a ~8% anual hasta 2029, y posiciona a VETGuardian como una herramienta que mejora el flujo de trabajo y el bienestar, complementaria a los diagnósticos y terapéuticas de Zomedica.
El seminario web se ofrece a través de webcast en vivo y los detalles de registro están disponibles en el sitio web de la empresa.
Zomedica (OTCQB:ZOMDF)가 Fourth Friday at Four 웹세미나를 2025년 10월 24일 4:00 p.m. ET에 발표하여 VETGuardian Zero Touch 모니터링 플랫폼을 선보입니다.
세션은 VETGuardian 모니터가 레이더 및 이미징 기술을 사용하여 무선이나 접촉 없이 심박수, 호흡, 체온의 연속적인 활력징후를 포착하는 방법을 검토합니다. 발표문은 2025년 애완동물 모니터링 시장이 $720백만 규모이며 2029년까지 연평균 약 8% 성장할 것으로 예측하고, VETGuardian을 Zomedica의 진단 및 치료법을 보완하는 작업 흐름 및 복지 개선 도구로 제시합니다.
웹세미나는 라이브 웹캐스트로 제공되며 등록 세부 정보는 회사 웹사이트에서 확인할 수 있습니다.
Zomedica (OTCQB:ZOMDF) a annoncé un webinaire Fourth Friday at Four le 24 octobre 2025 à 16h00 ET pour présenter la plateforme de surveillance VETGuardian Zero Touch.
La séance examinera comment le moniteur VETGuardian utilise la technologie radar et imaging pour capturer des signes vitaux en continu—rythme cardiaque, respiration et température corporelle—sans fils ni contact. Le communiqué cite un marché de surveillance vétérinaire de $720 millions en 2025, prévu de croître d’≈8% par an jusqu’en 2029, et positionne VETGuardian comme un outil améliorant le flux de travail et le bien-être, complémentaire aux diagnostics et thérapies de Zomedica.
Le webinaire est proposé via une diffusion en direct et les détails d’inscription sont disponibles sur le site de l’entreprise.
Zomedica (OTCQB:ZOMDF) kündigte ein Webinar Fourth Friday at Four am 24. Oktober 2025 um 16:00 Uhr ET an, um die VETGuardian Zero Touch-Monitoring-Plattform vorzustellen.
Die Sitzung wird erläutern, wie der VETGuardian-Monitor Radar- und Bildgebungstechnologie verwendet, um kontinuierliche Vitalparameter—Herzfrequenz, Atmung und Körpertemperatur—ohne Kabel oder Kontakt zu erfassen. Die Mitteilung verweist auf einen 720 Millionen US-Dollar großen veterinärmedizinischen Monitor-Markt im Jahr 2025, der voraussichtlich bis 2029 mit ca. 8% jährlicher Zuwachs wächst, und positioniert VETGuardian als workflow- und tierwohlverbesserndes Tool, das Zomedicas Diagnostik und Therapeutika ergänzt.
Das Webinar wird per Live-Webcast angeboten und Registrierungsdetails sind auf der Unternehmenswebsite verfügbar.
Zomedica (OTCQB:ZOMDF) أعلنت عن webinar Fourth Friday at Four في 24 أكتوبر 2025 الساعة 4:00 مساءً بتوقيت شرق الولايات المتحدة لعرض منصة VETGuardian Zero Touch للمراقبة.
ستستعرض الجلسة كيف يستخدم جهاز VETGuardian التقنيات الرادارية والتصويرية لالتقاط علامات الحياة الحيوية المستمرة—معدل ضربات القلب، التنفس ودرجة حرارة الجسم—دون أسلاك أو تماس. وتشير الإصدارة إلى سوق مراقبة بيطرية يبلغ $720 مليون في 2025، من المتوقع أن ينمو بمعدل تقريبي 8% سنوياً حتى 2029، وتضع VETGuardian كأداة لتحسين سير العمل والرفاهية تكمل تشخيصات Zomedica وعلاجاتها.
يتم تقديم الويبینار عبر بث مباشر وتتوفر تفاصيل التسجيل على موقع الشركة.
Zomedica (OTCQB:ZOMDF) 宣布将于 2025年10月24日美东时间下午4:00举行一个名为 Fourth Friday at Four 的网络研讨会，展示 VETGuardian Zero Touch 监控平台。
本次会议将回顾 VETGuardian 监控器如何使用 雷达和成像技术 来在不需要电线或接触的情况下持续捕捉生命体征——心率、呼吸和体温。公告称到2025年兽医监控市场规模为 $7.2亿美元，预计到2029年将以约 8% 的年增长率增长，并将 VETGuardian 定位为一款改进工作流程与福利的工具，作为 Zomedica 的诊断与治疗的补充。
该网络研讨会通过在线观看视频提供，注册链接可在公司网站上获得。
- None.
- None.
Insights
Zomedica highlights its contactless VETGuardian monitor and frames it as a potential revenue driver into a growing veterinary monitoring market.
Zomedica positions the VETGuardian Zero Touch monitor as a continuous, contactless vital‑sign solution that aims to reduce animal stress and improve clinical workflow. The company links the device to multiple revenue streams by adding monitoring to its diagnostic and therapeutic portfolio and cites a veterinary monitoring market of
Key dependencies include clinical adoption rates, regulatory acceptance where required, and demonstrable real‑world performance versus wired/contact systems. The webinar format provides outreach to clinicians and stakeholders but does not by itself validate reimbursement, sales, or technical efficacy.
Watch for concrete adoption signals after the webinar: published clinical validation data, initial commercial orders, and any announced distribution or partnership agreements over the next 6–18 months. The company can convert interest into measurable impact only if these milestones appear.
Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global market opportunities
ANN ARBOR, MI, MI / ACCESS Newswire / October 9, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that its upcoming "Fourth Friday at Four" webinar series, to be held on October 24, 2025 at 4:00 p.m. ET, will feature a deep dive into Zomedica's VETGuardian Zero Touch monitoring platform.
Key Learning Points
Market Expansion Opportunity: The veterinary monitoring market is projected to reach
$720 million in 2025, growing at ~8% annually through 2029, creating a sizable addressable market for the VETGuardian monitor.Differentiated Technology: The VETGuardian monitor is the only Zero Touch solution offering continuous monitoring without wires or contact, improving animal welfare and clinical workflow efficiency.
Strengthened Portfolio Value: The VETGuardian monitor adds a high-growth technology to Zomedica's expanding platform of gold-standard therapeutics and advanced diagnostics, creating multiple revenue streams.
The October 24th webinar will highlight how the VETGuardian monitor is reshaping veterinary monitoring through its pioneering Zero Touch approach. Unlike traditional systems that require wires or contact devices, the VETGuardian monitor leverages advanced radar and imaging technology to continuously capture patient vital signs, heart rate, respiration, and body temperature, all without physical contact. This innovation reduces patient stress, enhances safety for veterinary teams, and provides ongoing monitoring for critical cases.
With broader adoption of telemedicine and growing demand for personalized pet care, Zomedica believes the VETGuardian monitor represents not only a clinical advancement but also a significant growth driver in the veterinary monitoring market.
The Fourth Friday at Four webinars are designed to connect Zomedica directly with veterinarians, investors, and stakeholders, offering educational insight into the Company's expanding portfolio of innovative diagnostic and therapeutic technologies. The October 24th session will be available via live webcast, with details and registration accessible on the Company's website.
Sign up to join at : https://sholink.to/OctoberFourthFriday
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VETGuardian® Zero TouchTMmonitoring system, and Vetigel® hemostatic gel that rapidly stops bleeding-each designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
Investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
When is Zomedica's VETGuardian webinar for investors and veterinarians?
What features does the VETGuardian Zero Touch monitor highlight in the October 24, 2025 webinar?
How large is the veterinary monitoring market Zomedica cites for 2025 for ZOMDF?
How can investors join the Zomedica (ZOMDF) Fourth Friday at Four webcast?
What clinical benefits does Zomedica claim for the VETGuardian monitor?
Will the October 24, 2025 webinar discuss how VETGuardian fits Zomedica's product portfolio?
